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Abstract
Methotrexate (MTX) exerts an anti-inflammatory effect via its
metabolite adenosine, which activates adenosine receptors. The
A3 adenosine receptor (A3AR) was found to be highly expressed
in inflammatory tissues and peripheral blood mononuclear cells
(PBMCs) of rats with adjuvant-induced arthritis (AIA). CF101
(IB-MECA), an A3AR agonist, was previously found to inhibit the
clinical and pathological manifestations of AIA. The aim of the
present study was to examine the effect of MTX on A3AR
expression level and the efficacy of combined treatment with
CF101 and MTX in AIA rats. AIA rats were treated with MTX,
CF101, or both agents combined. A3AR mRNA, protein
expression and exhibition were tested in paw and PBMC
extracts from AIA rats utilizing immunohistochemistry staining,
RT-PCR and Western blot analysis. A3AR level was tested in
PBMC extracts from patients chronically treated with MTX and
healthy individuals. The effect of CF101, MTX and combined
treatment on A3AR expression level was also tested in PHA-
stimulated PBMCs from healthy individuals and from MTX-
treated patients with rheumatoid arthritis (RA). Combined
treatment with CF101 and MTX resulted in an additive anti-
inflammatory effect in AIA rats. MTX induced A2AAR and A3AR
over-expression in paw cells from treated animals. Moreover,
increased A3AR expression level was detected in PBMCs from
MTX-treated RA patients compared with cells from healthy
individuals. MTX also increased the protein expression level of
PHA-stimulated PBMCs from healthy individuals. The increase
in A3AR level was counteracted in vitro by adenosine deaminase
and mimicked in vivo by dipyridamole, demonstrating that
receptor over-expression was mediated by adenosine. In
conclusion, the data presented here indicate that MTX induces
increased A3AR expression and exhibition, thereby potentiating
the inhibitory effect of CF101 and supporting combined use of
these drugs to treat RA.
Introduction
Low-dose methotrexate (MTX) is the most widely used
antirheumatic drug and it is the 'gold standard' against which
other systemic medications are compared [1]. It has as its
A3AR = A3 adenosine receptor; ADA = adenosine deaminase; AIA = adjuvant-induced arthritis; BSA = bovine serum albumin; IB-MECA = 1-deoxy-
1-[6-[[(3-iodophenyl)methyl]amino]-9H-9-yl]-N-methyl-β-d-ribofura-nuronamide; MTX = methotrexate; NF-κB = nuclear factor-κB; PBMC = peripheral 
blood mononuclear cell; PBS = phosphate-buffered saline; PHA = phytohemagglutinin; RA = rheumatoid arthritis; RT-PCR = reverse transcription 
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target the enzyme dihydrofolate reductase, which is required
for reduction of dihydrofolate to tetrahydrolate. It is presumed
that cells exposed to MTX die as a result of reduced folate
depletion [2]. Adenosine, an additional active metabolite of
MTX, has been found to have potent anti-inflammatory effects,
and earlier studies [3,4] strongly support the notion that the
anti-inflammatory effect of MTX is attributed more to adenos-
ine than to tetrahydrolate. MTX increases the extracellular con-
centration of adenosine, where it is known to exert its anti-
inflammatory effect via suppression of inflammatory cytokines
such as tumour necrosis factor (TNF)-α, interleukin-6, or mac-
rophage inhibitory protein-1α [5-7]. It was further found that
the anti-inflammatory effect of adenosine is mediated via A2A
and the A3 adenosine receptors [8,9].
The highly selective A3 adenosine receptor (A3AR) agonist IB-
MECA (1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-9-yl]-
N-methyl-β-D-ribofura-nuronamide)  had an anti-inflammatory
effect in collagen-induced arthritis in DBA1 mice and adjuvant-
induced arthritis (AIA) in rats [10,11]. Interestingly, A3AR was
found to be over-expressed in the synovial and paw inflamma-
tory tissues as compared with corresponding tissues in nor-
mal, healthy animals. Moreover, receptor upregulation was
also identified in the peripheral blood mononuclear cells
(PBMCs) of AIA rats compared with control animals. Mecha-
nistically, on treatment with IB-MECA, downregulation of
A3AR expression level was noted in cells derived from the syn-
ovial tissue, most probably due to receptor internalization and
degradation. Subsequently, decreased levels of expression of
phosphatidylinositol-3 kinase and protein kinase B/Akt were
observed. The latter of these proteins is known to control the
nuclear factor-κB (NF-κB) signal transduction pathway. The
decreased levels of PKB/Akt resulted in failure to phosphor-
ylate IKK, which in turn resulted in inability to release NF-κB
from its IκB complex. These events led to decreased expres-
sion of NF-κB and TNF-α, resulting in apoptosis of synovial
cells. Remarkably, the PBMCs of AIA rats responded to IB-
MECA treatment in the same manner as did the synovial cells,
namely with receptor downregulation, suggesting that PBMCs
reflect the receptor situation in inflammatory tissues and may
have utility as a biomarker for monitoring response to IB-
MECA [12]. Furthermore, Gessi and coworkers [13] recently
noted upregulation of A3AR expression in phytohemagglutinin
(PHA)-stimulated PBMCs from healthy individuals. It thus
seems that A3AR expression correlates with cell activation or
pathogenicity.
Recently, IB-MECA (commercially known as CF101) was
tested in phase I clinical trials in healthy individuals. CF101, in
single and multiple oral dose studies, was found to be safe and
well tolerated, and the pharmacokinetics were linearly propor-
tional to dose [14]. In an early phase II clinical trial of CF101
conducted in patients with rheumatoid arthritis (RA), the drug
was well tolerated and conferred benefit as monotherapy [15].
Most biological disease-modifying antirheumatic drugs cur-
rently are given in combination with MTX [16]. Therefore, the
aim of the present study was to evaluate the efficacy of com-
bined MTX+CF101 treatment. We found that MTX treatment
increased expression of A3AR, rendering inflammatory cells
more susceptible to CF101. Combined treatment of AIA rats
with MTX and CF101 enhanced the anti-inflammatory effect of
each drug. In addition, we found A3AR to be over-expressed in
PBMCs of MTX-treated patients and in activated cells from
healthy individuals. The molecular mechanisms involved are
explored.
Materials and methods
Reagents
The A3AR agonist IB-MECA was synthesized for Can-Fite
BioPharma Ltd (Petah-Tikva, Israel) by Albany Molecular
Research Inc (Albany, NY, USA) and is referred to as CF101
in the following text. A stock solution of 10 mmol/l was pre-
pared in DMSO and further dilutions were performed. RPMI,
foetal bovine serum and antibiotics for cell cultures were
obtained from Beit Haemek (Haifa, Israel). The A3AR antago-
nist MRS1523 was purchased from Sigma (St. Louis, MO,
USA) and diluted in the same manner as for CF101. Rabbit
polyclonal antibodies against rat and human A3AR as well as
rat A2AAR were purchased from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA, USA). MTX, PHA, adenosine and adeno-
sine deaminase (ADA) were purchased from ABIC (Beit
Shemesh, Israel). Dipyridamole was purchased from Sigma.
Effect of CF101 and MTX on development of AIA
Female Lewis rats, aged 9 weeks, were obtained from Harlan
Laboratories (Jerusalem, Israel). Rats were maintained on a
standardized pellet diet and supplied with tap water. Experi-
ments were performed in accordance with the guidelines
established by the Institutional Animal Care and Use Commit-
tee at Can-Fite BioPharma, Petach Tikva, Israel. The rats were
injected subcutaneously at the tail base with 100 μl suspen-
sion composed of incomplete Freund's adjuvant with 10 mg/
ml heat killed Mycobacterium tuberculosis H37Ra (Difco,
Detroit, MI, USA). Each group included 10 animals.
For the prophylactic treatment study, MTX treatment (0.25
mg/kg intraperitoneally) was administered once weekly, start-
ing 3 days after disease induction. CF101 (100 μg/kg) was
orally administered by gavage, twice daily, starting at disease
onset. The study also included a group treated with a combi-
nation of MTX and CF101. The control group received vehicle
only (DMSO at a dilution corresponding to that of CF101).
For the therapeutic treatment study, MTX (0.75 mg/kg intra-
peritoneally, once weekly) as well as CF101 (100 μg/kg orally,
twice daily) were initiated on disease onset. As in the prophy-
lactic study, a group treated with a combination of MTX and
CF101 was included.Available online http://arthritis-research.com/content/8/6/R169
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Clinical disease activity score was assessed as follows. The
animals were inspected every day for clinical arthritis. The
scoring system ranged from 0 to 4 of each limb: 0 indicates no
arthritis, 1 indicates redness or swelling of one toe/finger joint,
2 indicates redness and swelling of more than one toe/finger
joints, 3 indicates involvement of ankle and tarsal-metatarsal
joints, and 4 indicates redness or swelling of the entire paw.
The four individual leg scores were added together to yield a
total clinical score.
At the end of the study the legs were removed up to the knees,
fixed in 10% formaldehyde, decalcified, dehydrated, paraffin
embedded and cut into 4 μm sections. They were then stained
by haematoxylin and eosin, and morphopathological assess-
ment was performed.
Pathological assessments were performed using semiquanti-
tative grading scales from 0 to 4 for the following parameters:
the extent of inflammatory cell infiltration into the joint tissues,
synovial lining cell hyperplasia, pannus formation, joint carti-
lage layer destruction and bone damage and erosion: 0 indi-
cates normal; 1 indicates minimal loss of cortical bone at a few
sites; 2 indicates mild loss of cortical trabecular bone; 3 indi-
cates moderate loss of bone at many sites; 4 indicates marked
loss of bone at many sites; and 5 indicates marked loss of
bone at many sites, with fragmenting and full thickness pene-
tration of inflammatory process or pannus into the cortical
bone. The means of all of the histological parameter scores
were summated to yield an overall 'histology score'.
In addition, blood samples were collected and subjected to
Ficoll hypaque gradient. The PBMCs were then washed with
phosphate-buffered saline (PBS), and protein extracts were
prepared as detailed below.
The hind paws were dissected above the ankle joint. The bony
tissue was broken into pieces, snap frozen in liquid nitrogen
and stored at -80°C until use. The paw tissues were added to
RIPA extraction buffer (4 ml/g tissue) contaning 150 mmol/l
NaCl, 50 mmol/l Tris, 1% NP40, 0.5% deoxycholate and 0.1%
SDS. Tissues were homogenized on ice with a polytron, cen-
trifuged and the supernatants were subjected to Western Blot
analysis.
Effect of dipyridamole on the expression of A3AR in 
PBMCs from naïve rats
Dipyridamole (5 mg/kg intraperitoneally) was administered
once to naïve rats and blood samples were drawn 2, 6, 24 and
48 hours after dipyridamole administration and subjected to
Ficoll hypaque gradient. The PBMCs were then washed with
PBS and protein extracts were prepared as detailed below.
Immunohistochemistry staining of paraffin-embedded 
slides of paws tissues derived from AIA rats
The paraffin on the slides was melted from the sections, which
were placed in xylene three times for 30 min each. The tissues
were hydrated with serial dilutions of ethanol and then antigen
was retrieved by heating with citrate buffer at 95°C for 30 min.
The slides were allowed to cool down and then washed three
times in PBS. Endogenous peroxidase quenching was per-
formed by washing the sections with fresh 20% hydrogen per-
oxide in methanol for 20 min. The sections were then blocked
by incubating in 5% normal goat serum in PBS-BSA 0.1% for
2 hours.
The primary antibody (Novus Biologicals Inc., Littleton, CO,
USA) was diluted in 0.1% PBS-BSA and incubated overnight
at room temperature. After three washes in 1× PBS, the slides
were incubated in 0.5% biotinilated secondary antibody in
Table 1
Characteristic of patients newly and chronically treated with MTX
Characteristic RA patients
Newly MTX treated Chronically MTX treated
Age (years) 48.5 ± 5.89 59.58 ± 2.42
Disease duration (years) 4.37 ± 2.07 6.6 ± 0.97
CRP (mg/l) 10.75 ± 2.01 9.04 ± 1.65
ESR (mm/hour) 31.75 ± 0.63 33.3 ± 4.39
Swollen joint count 13.25 ± 2.56 3.19 ± 0.88
Tender joint count 10.5 ± 2.63 5 ± 0.86
Patient global assessment (VAS) 32.26 ± 4.41
CRP (DAS28-4) 3.23 ± 0.31
ESR (DAS28-4) 4.11 ± 0.3
Values are expressed as mean ± standard error. CRP, C-reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, 
methotrexate; RA, rheumatoid arthritis; VAS, visual analogue scale.Arthritis Research & Therapy    Vol 8 No 6    Ochaion et al.
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PBS-BSA 0.1% for 1 hour at room temperature and then sub-
jected to an avidin-biotin complex After another wash the
slides were incubated with DAB substrate, washed in tap
water (to dispose of the DAB) and inactivated with bleach. A
light haematoxylin counterstain was performed and the haema-
toxylin was then removed by quick dip in acid alcohol and the
slides were washed in ammonia water, dehydrated and
mounted with Permount.
Human blood sample collection and separation
Blood samples were collected from healthy individuals and
from patients with RA who were either newly and chronically
treated with MTX. Protocols for the study were approved by
the hospitals' ethical committees as was the blood sample col-
lection. Healthy individuals and RA patients provided signed,
informed consent prior to blood withdrawal. Patient character-
istics are summarized in Table 1.
To separate PBMCs, heparanized blood (20 ml) was sub-
jected to Ficoll hypaque gradient. The PBMCs were then
washed with PBS and subjected to the various assays.
Double immunofluorecence staining of PBMCs of RA 
patients
PBMCs (1 × 106 cells) were smeared on electrophorized
glass slide and fixed with 75% ethanol for 2 min. The slides
were then blocked with normal horse serum for 1 hour at room
temperature in a humidified chamber, after which a mouse
monoclonal CD4 (Santa Cruz Biotechnology; Clone MT310,
1:50 dilution) primary antibody was incubated overnight at
room temperature. After rinsing thoroughly with PBS, a rhod-
amine-tagged secondary antibody (Vector Laboratories, Burl-
ingame, CA, USA; 1:200 dilution) was incubated overnight in
the dark. Then the slides were rinsed with PBS, blocked with
normal goat serum and incubated with a rabbit polyclonal anti-
A3AR antibody (Chemicon International, Temecula, CA, USA;
AB9111, 1:100 dilution) overnight. Cells were rinsed with
PBS and a second, fluorescein-tagged anti-rabbit antibody
was incubated for 1 hour in the dark. Finally, slides were
rinsed, coverslipped with an aquous based mounting media
(Vectashield; Vector Laboratories) and visualized in a Nikon
ultraviolet inverted microscope and processed with a decon-
volution software (Slidebook 4.0; Intelligent Imaging, Denver,
CO, USA).
Activation of PBMCs
PBMCs (2 × 106 cells/ml) from healthy individuals or from
MTX-treated RA patients were incubated in cell cultures with
RPMI 1640 supplemented with 10% FBS. PBMCs from
healthy individuals were activated with PHA (5 μg/ml) for 24
hours. MTX (1 μmol/l) was added for an additional 27 hours.
ADA (1 unit/ml), CF101 (10 nmol/l), or MRS1353 (10 nmol/l)
was added to the culture system for the last 3 hours. In another
set of experiments PBMCs from healthy individuals were incu-
bated for 27 hours with adenosine (25 μmol/l), and ADA (1
unit/ml) was added to the culture system for the last 3 hours.
PBMCs from MTX-treated RA patients were incubated for 1
hour with CF101 (10 nmol/l). At the end of the incubation time
in all of the above experiments, the PBMCs were collected
from the culture plates and protein extracts were prepared.
Western blot analysis of A3AR and additional signalling 
proteins in PBMCs
Western blot analyses were carried out according to the fol-
lowing protocol. Samples were rinsed with ice-cold PBS and
transferred to ice-cold lysis buffer (TNN buffer: 50 mmol/l Tris
buffer [pH 7.5], 150 mmol/l NaCl and NP40). Cell debris was
removed by centrifugation for 10 min at 7500 g. Protein con-
centrations were determined using the BioRad protein assay
dye reagent (BioRad Laboratories, Hercules, CA, USA). Equal
amounts of the sample (50 μg) were separated by SDS-
PAGE, using 12% polyacrylamide gels. The resolved proteins
were then electroblotted onto nitrocellulose membranes (Sch-
leicher & Schuell, Keene, NH, USA). Membranes were
blocked with 1% BSA and incubated with the desired primary
antibody (dilution 1:1000) for 24 hours at 4°C. Blots were
then washed and incubated with a secondary antibody for 1
hour at room temperature. Bands were recorded using BCIP/
NBT color development kit (Promega, Madison, WI, USA).
Analysis of A3AR protein expression level in patient PBMCs
was performed as follows. Samples from each of four RA
patients were run in the same gel with a pool of samples from
four healthy individuals, designated the standard. The blots
were quantified by densitometric analysis and the ratio of RA
patient/standard was calculated. Blots of mitogen stimulated
cells were quantified against β-actin. The data presented in the
figures are representative of at least three different
experiments.
RT-PCR analysis of formalin-fixed paraffin-embedded 
paw tissue slides
Tissue sections of paws derived from AIA rats treated with
vehicle, MTX, CF101, or MTX+CF101 were mounted on
slides and then deparaffinized in xylen and rehydrated by
washing in serial dilutions of ethanol. Slides were used imme-
diately or stored at -80°C until use. After rehydration, 20 μl of
solution A (1.25× PCR buffer [200 mmol/l Tris-HCl, 500
mmol/l KCl], 6.25 mmol/l MgCl2, 5 U RNasin [Promega], 2
mmol/l DTT, 1 U RQ1 RNase-free DNase [Promega]) was
directly applied to the marked area. The marked area was com-
pletely scraped off the slide using a pipette tip, and neoplastic
tissue or normal tissue was collected into different microcen-
trifuge tubes. The samples were treated with proteinase K at a
final concentration of 0.1 mg/ml. The samples were incubated
at 37°C for 1 hour to allow for DNA digestion. Cells lysate
were heated to 95°C for 15 min in order to inactivate DNase
and proteinase K. Following centrifugation at 14,000 rpm for
5 min, 17 μl of the supernatant was transferred to a separate
tube and 4 μl of RT mixure (5 mmol/l dNTPs, 2.5 μmol/l ran-Available online http://arthritis-research.com/content/8/6/R169
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dom hexamer, 5 U RNasin, 100 U SuperScript One Step RT-
PCR with Platinum Taq (Invitrogene, San Diago, CA, USA)
and the primers for rat A3AR (245 up CTA GCA CTG GCA
GAC and 245 down CAG CAG AGG CCC AGG) were
added.
The RT reaction was performed at 45°C for 45 min, followed
by heating to 99°C for 5 min; then, 50 cycles at 94°C for 30
s, 50°C for 75 s and 73°C for 45 s, and an extension of 73°C
for 7 min were performed. Products were electrophoresed on
2% agarose gels, stained with ethidium bromide and visual-
ized with ultraviolet illumination. The specificity of the RT-PCR
reaction was confirmed by size determination on agarose gels
in comparison with a positive control, from RNA extracted
using standard techniques, and by sequencing the RT-PCR
product and comparing the sequences with the known
sequences (ADORA3-L77729, L77730). The optical density
of the bands (Et-Br) was quantified using an image analysis
system. This analysis was performed on tissues from three dif-
ferent experiments.
Statistical analysis
To analyze differences in clinical score between the four study
Figure 1
Effect of CF101 and prophylactic or therapeutic MTX treatment on AIA rats Effect of CF101 and prophylactic or therapeutic MTX treatment on AIA rats. Rats were injected subcutaneously at the tail base with 100 μl of a sus-
pension composed of incomplete Freund's adjuvant and 10 mg/ml heat killed Mycobacterium tuberculosis. (a) Clinical score. Combined treatment 
with MTX (prophylactic treatment) + CF101 yield significantly lower values than treatment with each of the agents alone; also, all treatments yielded 
lower scores than control group. (b) The clinical score with combined therapeutic MTX treatment + CF101 was significantly lower than that in the 
other groups. (c, d) Morphopathological score. In AIA animals complete distruction of the cartilage and the bone, as well as severe inflammation in 
the hind paws, was noted. Treatment with a combination of MTX and CF101 preserved the normal features of the paw. AIA, adjuvant-induced arthri-
tis; MTX, methotrexate.Arthritis Research & Therapy    Vol 8 No 6    Ochaion et al.
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groups (CF101, MTX, MTX+CF101 [combined treatment]
and control), we used analysis of variance (ANOVA) with
repeated measures from days 8 to 25 for prophylactic treat-
ment and from days 14 to 20 for therapeutic treatment. To test
differences in trends during the study between the four study
groups, we used ANOVA using Dunnet method to evaluate
differences between each of the study groups and the control
group: for prophylactic treatment this was from days 20 to 25,
adjusted to baseline values (day 8); and for therapeutic treat-
ment this was from days 14 to day 20, adjusted to baseline val-
ues at day 14. ANOVA using Dunnet method was utilized to
evaluate differences between each of the study groups and
the combined treatment group (CF101+MTX): for prophylac-
tic treatment this was from days 20 to 25, adjusted to baseline
values (day 8); and for therapeutic treatment this was from
days 14 to 20, adjusted to baseline values at day 14. The data
were analyzed using SAS software (SAS Institute, Cary, NC,
USA).
The Student's t-test was used in the Westen blot analysis, and
P < 0.05 was considered statistically significant.
Results
Effect of MTX, CF101, and MTX+CF101 treatment on 
development of AIA in rats
In the prophylactic treatment study, about 21 days after immu-
nization most of the vehicle-treated animals progressively
developed arthritis. Comparing the four groups using ANOVA,
CF101 treatment (100 μg/kg, given orally twice daily, starting
on onset of disease) and MTX treatment (given once weekly,
starting on day 3 after disease induction) resulted in a statisti-
cally significant difference between the study groups and the
control group (Figure 1a; P < 0001). In order to identify the
source of those differences, ANOVA with the Dunnet method
was used. In general, up to day 20 a differences in trends were
observed between the groups, but the differences were not
statistically significant. From day 20 on, a clear trend toward
lower values in the combined treatment group (MTX+CF101)
was observed, as compared with the control group and each
of the other treatment groups (Figure 1a).
In the therapeutic treatment study, in which all of the treat-
ments were initiated at the onset of disease, clinical score in
the MTX and CF101 combined treatment group was found to
be statistically significantly lower than that in the control group.
Moreover, clinical score in the group receiving combined treat-
ment with MTX and CF101 was always lower than that the
other groups. From day 17 the trend becomes statistically sig-
nificant (Figure 1b).
Histological evaluation of the paws in the vehicle-treated
arthritic animals revealed complete distruction of cartilage and
bone, which were replaced by granulation tissue. Severe
inflammation infiltration was also noted. In the MTX treated
group bone destruction was also observed, with a few rem-
nants of bone spicutels seated in the granulation tissue. The
degree of inflammatory infiltration was less than that observed
in the control group, resulting in a 47% decrease in histologi-
cal score. CF101 treatment resulted in a 75% decrease in his-
tological score, which was manifested as a mild inflammatory
infiltration. The articular space, cartilage, bone and bone mar-
row appeared normal. Treatment with MTX in combination
with CF101 was associated with normal cartilage and bone
architecture, and with an histological score that was almost
zero (Figure 1c,d).
Effect of MTX, CF101 and MTX+ CF101 treatment on 
exhibition and expression of A3AR in paw and PBMCs 
from AIA rats
Immunohistochemistry staining of paw sections derived from
AIA rats revealed the of A3AR exhibition in the control paw,
which was markedly increased with MTX treatment. In the
CF101-treated group, A3AR exhibition was much lower and
the receptor was barely detected at all in MTX+CF101-treated
paw sections (Figure 2).
Analysis of mRNA and protein A3AR expression in paw
extracts from the MTX-treated group revealed an increase
compared with the vehicle-treated group. In the CF101-treat-
ment and the MTX+CF101-treated groups, receptor down-
regulation was noted, supporting previous studies
demonstrating that receptor downregulation represents a
functional response to the agonist (Figure 3a,b). In PBMCs
from the animals treated with MTX, CF101 and MTX+CF101,
similar results to those noted in the paw extracts were
recorded (Figure 3c).
We further examined the effect of MTX on expression of A3AR
protein compared with A2AAR protein in paw extracts. Figure
3d shows that the expression levels of both receptors is
increased with MTX treatment.
To explore the molecular mechanism involved in the increased
expression of A3AR with MTX treatment, we assumed this
phenomenon to be attributed to elevated adenosine levels in
the cell microenvironment. We thus treated naïve rats with
dipyridamole, a nucleoside transporter inhibitor that increases
extracellular adenosine concentration. Indeed, dipyridamole
induced A3AR over-expression in PBMCs from treated rats
(Figure 4).
A3AR expression in PBMCs from RA patients
Our next step was to examine A3AR expression level in
PBMCs from MTX-treated RA patients. Figure 5a shows four
blots from newly MTX treated RA patients. Upregulation of
A3AR expression was observed in all patients after 10 weeks
of MTX treatment. There was a marked statistically significant
increase (P < 0.01) in A3AR expression in PBMCs from RA
patients undergoing chronic MTX treatment (n = 30) in com-Available online http://arthritis-research.com/content/8/6/R169
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Figure 2
Immunohistochemistry analysis of A3AR expression in paws from AIA rats Immunohistochemistry analysis of A3AR expression in paws from AIA rats. We conducted immunohistochemistry staining of paraffin-embedded sec-
tions of paw from MTX-treated, CF101-treated and MTX+CF101-treated AIA rats. MTX treatment induced receptor expression, and treatment with 
CF101 alone or in combination with MTX resulted in receptor downregulation. A3AR, A3 adenosine receptor; AIA, adjuvant-induced arthritis; MTX, 
methotrexate.
Figure 3
Ex vivo analysis of A3AR expression level in paw and PBMCs from AIA rats Ex vivo analysis of A3AR expression level in paw and PBMCs from AIA rats. (a, b) MTX treatment induced expression of A3AR mRNA and protein, 
and CF101 treatment resulted in receptor downregulation. (c) This was reflected in the PBMCs. (d) Expression of A2AAR was also induced in paw 
extracts derived AIA rats treated with MTX. A3AR, A3 adenosine receptor; AIA, adjuvant-induced arthritis; MTX, methotrexate; PBMC, peripheral 
blood mononuclear cell.Arthritis Research & Therapy    Vol 8 No 6    Ochaion et al.
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parison with healthy individuals (Figure 5b). No correlation
between A3AR expression level, MTX dose, or DAS28 (Dis-
ease Activity Score) was found.
In addition, we performed double immunofluorecence staining
on PBMCs from RA patients to identify A3AR on the cell sur-
face of CD4+ T lymphocytes. Figure 5c shows massive A3AR
staining on the CD4+ T cells.
In an additional set of experiments we looked at the in vitro
effect of CF101 on A3AR protein level in PBMCs from MTX-
treated RA patients. The cells were cultured in the presence
and absence of CF101 for 1 hour. Figure 5d shows A3AR
over-expression in the RA samples compared with control
samples. CF101 treatment induced A3AR downregulation,
reflecting the response of PBMCs to the drug; this suggests
that receptor expression may have utility as a biological predic-
tion marker.
Effect of MTX+CF101 on A3AR expression level in PHA-
stimulated PBMCs from healthy individuals
To further investigate the effect of MTX on A3AR expression,
we used an in vitro system of PHA-stimulated PBMCs from
healthy individuals. We found that A3AR expression level was
increased on MTX treatment. Also, introduction of ADA to the
culture system reverted this effect, suggesting that receptor
over-expression was induced by adenosine, a metabolite of
MTX (Figure 6a). Finally, the natural ligand adenosine induced
an increase in A3AR expression when added to the culture
system, supporting the notion presented above that adenosine
acts as mediator of the MTX effect (Figure 6b).
Introduction of CF101 to MTX-treated, PHA-stimulated cells
induced receptor downregulation, which was counteracted by
the A3AR antagonist MRS1535 (Figure 6c).
Discussion
The present study shows that combined treatment with
CF101 and MTX has an additive anti-inflammatory effect,
which is indicated by a decrease in the clinical and pathologi-
cal manifestations of AIA. Mechanistically, MTX induced an
increase in A3AR expression level in inflamed tissues and in
PBMCs, thereby rendering the cells more susceptible to
CF101 treatment. Interestingly, MTX given either in prophylac-
tic or therapeutic mode in combination with CF101 resulted in
the same additive effect.
To explore the mechanism underlying the efficacy of the com-
bined treatment, we first examined the mode of action of MTX.
It acts as an antagonist of folic acid, subsequently inhibiting
the synthesis of purines and pyrimidines. It was further sug-
gested that the anti-inflammatory effect of MTX is due to ade-
nosine, which is known to exert potent anti-inflammatory effect
[3,4]. More specifically, MTX polyglutamates inhibit the activity
of the enzyme aminoimidazolecarbox-amidoadenosineribonu-
cleotide transformylase [17,18]. This enzyme has a direct
inhibitory effect on two additional enzymes: ADA, which
metabolizes adenosine to inosine; and AMP deaminase, which
converts adenosine to AMP. This chain of events results in
intracellular accumulation of adenosine, which is then released
into the extracellular environment [19]. The working hypothe-
sis of the present study was that the increase in adenosine
level may act via an autocrine pathway and induce the expres-
sion of its own receptors, in this case A3AR. Indeed, MTX
treatment increased both mRNA and protein levels of A3AR in
the inflammatory tissue (paw) of AIA rats, indicating that
increased gene expression and translation took place. An
increase in protein A3AR expression was also noted in the
PBMCs from the animals. Interestingly, increased A2AAR pro-
tein levels were also noted in paw samples from MTX-treated
animals. Ravid and coworkers [20] have shown that activation
of A2AR increases A3AR promoter activity. It could therefore be
Figure 4
Effect of dipyridamole on the expression of A3AR in PBMCs from naïve rats Effect of dipyridamole on the expression of A3AR in PBMCs from naïve rats. Dipyridamole (5 mg/kg intraperitoneally) was administered once to naïve 
rats and blood samples were drawn 2, 6, 24 and 48 hours after dipyridamole administration. Dipyridamole induced A3AR upregulation in PBMCs 
derived from treated rats. A3AR, A3 adenosine receptor; PBMC, peripheral blood mononuclear cell.Available online http://arthritis-research.com/content/8/6/R169
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suggested that over-expression of A2AAR plays a role in the
increased level of A3AR that occurs with MTX treatment.
Moreover, A3AR protein level was raised in RA patients treated
with MTX. This was attributed to the increase in A3AR expres-
sion detected on CD4+ T cells from RA patients compared
with CD4+ T cells from healthy individuals.
In this report we present two lines of experimental evidence
that support a role for adenosine in modulating A3AR expres-
sion in response to MTX treatment. In vitro studies with
PBMCs showed that MTX treatment induced an increase in
A3AR expression that was reversed on treatment with ADA.
Adenosine mimicked the effect of MTX and induced an eleva-
tion in A3AR expression. In vivo dipyridamole, an inhibitor of
nucleoside transporters, known to increase adenosine levels,
induced A3AR over-expression in PBMCs from treated rats.
These data led to the conclusion that MTX, via the metabolite
adenosine, induces elevation in A3AR expression.
Receptor density was previously reported as an important fac-
tor that controls cell response to a given agonist [21-23]. It
may be suggested that A3AR upregulation, mediated by MTX,
preconditions cells to the effect of CF101, resulting in a more
potent anti-inflammatory effect.
An additional important finding of the study is that inflamma-
tory cells and PBMCs from CF101-treated AIA rats, as well as
the PBMCs cultured in vitro with CF101, responded to
agonist treatment and to combined treatment with receptor
downregulation. The A3AR antagonist MRS 1353 counter-
acted the downregulation induced by the combined treatment.
This finding supports the notion presented above that the
effect of CF101 alone or in combination with MTX is solely
mediated via A3AR, without the involvement of additional
receptors. Our earlier studies in tumor cells showed that, on
binding of an agonist such as CF101 to tumor cells, receptor
is internalized and degraded within the cytoplasm [24,25].
This is followed by initiation of downstream signal transduction
pathways, leading to inhibition of tumor growth. A few hours
later receptor is resynthesized and recycled to the cell surface.
Recently, we reported a similar chain of events in the synovial
cells of AIA rats treated with CF101. A3AR receptor levels
Figure 5
A3AR expression level in PBMCs from RA patients A3AR expression level in PBMCs from RA patients. (a) Newly MTX treated RA patients. Western blots of the four patients at baseline and 10 weeks 
after MTX treatment are presented. Representative Western blots are shown at the bottom. (b) RA patients undergoing chronic treatment with MTX. 
Results are expressed as means ± standard error for 30 patients. (c) Double-stained immunofluorecence analysis of PBMCs from RA patients. 
A3AR expression on the cell surface of the CD4+ T cells was found. (d) Incubation of PBMCs from MTX-treated RA patients for 1 hour in RPMI 1640 
supplemented with 10% foetal bovine serum in the presence of with CF101 (10 nmol/l) resulted in decreased expression of A3AR. A3AR, A3 adeno-
sine receptor; AIA, adjuvant-induced arthritis; MTX, methotrexate; PBMC, peripheral blood mononuclear cell; RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 8 No 6    Ochaion et al.
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were downregulated on agonist treatment, followed by modu-
lation of cell signaling proteins that belong to the NF-κB signal
transduction pathway, resulting in decreased expression of
TNF-α and inhibition of the inflammatory process [12]. It thus
seems that if A3AR upregulation is characteristic of inflamma-
tion, then CF101 treatment induces receptor downregulation,
which reflects receptor functionality, and modulation of key
signaling proteins that control the inflammatory process. Inter-
estingly, introduction of CF101 to in vitro culture of PBMCs
derived from MTX-treated RA patients resulted in A3AR down-
regulation. The ability to assess in vitro the response to CF101
may be utilized in the future to predict the response of individ-
ual patients to the drug before treatment.
The mechanism presented in this study by which MTX elevates
A3AR expression may also account for the anti-inflammatory
effect of this drug when given as a standalone therapy. Under
physiological conditions A3AR is not activated because ade-
nosine has the lowest affinity value to this receptor (A2A > A1
> A2B > A3). On MTX treatment the adenosine level goes up,
thereby activating A3AR and resulting in an anti-inflammatory
effect [3,4,26].
High expression levels of A3AR in inflamed or activated cells
were previously reported in other inflammatory conditions. A
selective, approximately 10-fold upregulation of A3AR mRNA
and protein was consistently found in nonpigmented ciliary
epithelium of eyes of patients with pseudo-exfoliation syn-
drome, with and without glaucoma, as compared with normal
and glaucomatous control eyes [27]. Blair and coworkers [28]
showed that A3AR transcript abundance is greater in lung tis-
sue and eosinophils from individuals with airway inflammation
than in normal lung. A3AR elevation was also reflected in eosi-
nophils derived from the peripheral blood of the same patients.
Treatment of eosinophils with IB-MECA inhibited platelet-acti-
vating factor induced eosinophil chemotaxis [28]. Moreover,
Gessi and coworkers [29] reported that A3AR is induced in
activated PBMCs from healthy individuals, and further demon-
strated that the CD4+ T cells are the subpopulation of cells
that over-express the receptor. Taken together, it may be con-
cluded that A3AR upregulation is a characteristic of activated
cells, and is noted in cells of inflammatory origin and is
reflected in PBMCs.
To summarize, enhanced anti-inflammatory effect takes place
on treatment of AIA rats with the combination of MTX and
CF101. This effect is mediated via adenosine, which accumu-
lates in cells on MTX treatment, leading to increased levels of
A3AR, thereby rendering the cells more sensitive to the effect
of CF101. We recently reported a positive response of RA
patients to CF101 treatment (as a standalone therapy) in a
phase IIa study [15]. The results of the present study provide
justification for a phase IIb study combining CF101 with MTX
treatment in a population of RA patients.
Figure 6
Effect of MTX on A3AR expression level on PBMCs from healthy  individuals Effect of MTX on A3AR expression level on PBMCs from healthy indi-
viduals. (a) PBMCs (2 × 106 cells/ml) from healthy individuals were 
incubated in RPMI 1640 supplemented with 10% foetal bovine serum 
and activated with PHA (5 μg/ml) for 24 hours. MTX (1 μmol/l) was 
added for an additional 27 hours and ADA (1 unit/ml) for the last 3 
hours. A3AR expression level was induced by MTX treatment. The intro-
duction of ADA to the culture system reverted this effect and induced 
downregulation of the receptor level. (b) PBMCs (2 × 106 cells/ml) 
were incubated for 27 hours with adenosine (25 μmol/l) and ADA (1 
unit/ml) was added to the culture system for the last 3 hours. Adenos-
ine induced upregulation of A3AR expression level whereas the addition 
of ADA decreased the receptor level. (c) PBMCs from healthy individu-
als were incubated with 10% foetal bovine serum and activated with 
PHA (5 μg/ml) for 24 hours. MTX (1 μmol/l) was added for an addi-
tional 27 hours and CF101 (10 nmol/l), in the presence or absence of 
MRS1523 (10 nmol/l), was introduced into the culture system for the 
last 3 hours. CF101 introduction to MTX-treated, PHA-activated 
PBMCs induced receptor downregulation, and the MRS1523 counter-
acted this effect. A3AR, A3 adenosine receptor; ADA, adenosine deam-
inase; MTX, methotrexate; PBMC, peripheral blood mononuclear cell; 
PHA, phytohemagglutinin; RA, rheumatoid arthritis.Available online http://arthritis-research.com/content/8/6/R169
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Conclusion
Using an in vivo model of AIA in rats, we demonstrated that
combined treatment with CF101 and MTX resulted in an addi-
tive anti-inflammatory effect. Mechanistically, we found that
MTX induced an increase in the expression level of A3AR, ren-
dering the inflammatory cells more susceptible to CF101
treatment. Adding further support to these findings were data
from the MTX-treated RA patients, who exhibited A3AR over-
expression in PBMCs.
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